Sandoz announces that it has signed an agreement to acquire the US ranibizumab biosimilar Cimerli (ranibizumab-eqrn) from Coherus BioSciences, for a consideration of $170 million.

Cimerli is interchangeable with Lucentis for all indications in which the latter is approved. The transaction is expected to close in the first half of 2024, subject to customary conditions and approvals.

This acquisition will enable Sandoz to offer even more treatment options to US patients with vision impairment or loss, and to 'build a more robust ophthalmic platform to support future product launches'.

Copyright (c) 2024 CercleFinance.com. All rights reserved.